Should the reform be accepted, it will build upon a previous change made by the NCAA, which raised the THC level for a positive test from 35 nanograms (ng) per milliliter (ml) to 150, aligning it with the rules of the World Anti-Doping Agency (WADA).
Committee chair James Houle underlined the significance of member institutions having a say in such a significant policy shift, stressing the need for new research to support the well-being of student-athletes.
The committee also recommended that a comprehensive educational approach be developed to accompany any prospective changes to cannabinoid regulation. This move is consistent with a larger trend observed in professional sports groups, reflecting the growing acceptability of state-level cannabis legalization.
The NBA recently removed marijuana from its list of prohibited substances and allowed players to engage with cannabis brands. Sports regulators in Nevada have also taken steps to shield athletes from penalties related to marijuana use or possession, aligning with state law.
In 2021, the UFC announced it would no longer penalize fighters for positive cannabis tests. Moreover, the NYMSL partnered with a Kentucky-based CBD company, following the lead of the MLB and teams such as the Chicago Cubs and Kansas City Royals. MLB entered a league-wide partnership with a well-known CBD brand in 2022, designating them the “Official CBD brand of MLB.”
While these changes have garnered support from advocates, criticism has arisen toward WADA for maintaining its cannabis ban. A panel within WADA argued that marijuana use by athletes runs counter to the “sport’s enthusiasm” and could set a negative example while potentially endangering others.
Advocates have called for WADA to consider reforms, especially following the suspension of U.S. runner Sha’Carri Richardson from Olympic events due to a positive THC test in 2021. Subsequently, the U.S. Anti-Doping Agency (USADA) and the White House, including President Joe Biden, expressed support for policy changes, with congressional lawmakers echoing these sentiments.
The cannabis industry, including many of its leading actors such as Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON), has long believed that marijuana has been maligned based on many unfounded misconceptions. When entities such as the NCAA reverse their prohibitive drug policies, advocates are vindicated as science rebuts many of the wrong premises upon which this plant was outlawed.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
“Quiet quitting” is a phenomenon where employees put in the minimum effort, time and enthusiasm required of them at their jobs and don’t go out of their way to create any extra value for their employers. The trend has picked up a lot of steam in recent years as employees have begun prioritizing a strict work-life balance and finding value in their hobbies and other experiences rather than work.
Increased employee demands and stagnating wages coupled with increasing living costs have made many employees question if going the extra mile, whether it’s through arriving early, taking part in nonmandatory meetings or leaving late, adds any value to their lives.
Recent research now reveals that there may be a correlation between psilocybin or magic mushroom use and reduced overtime hours in psychedelic users who work full time. University of Bamberg postdoctoral researcher and study author Benjamin A. Korman says he was motivated to carry out the study due to the growing body of research on the therapeutic efficacy of psychedelics, increasing rates of quiet quitting and reports that employees are using more psychedelics.
He analyzed National Survey and Drug Use and Health (NSDUH) data collected from more than 217,000 fully employed individuals aged 18 and older between 2002 and 2014. The researchers found a positive association between psychedelics and less overtime worked, with individuals who had used psilocybin at least once in their lives working fewer overtime hours compared to nonpsilocybin users.
Psilocybin is part of a psychedelic research renaissance that has connected various psychedelics with major reductions in the symptoms of mental disorders including anxiety, depression and post-traumatic stress disorder (PTSD). Research has also found that psychedelics can cause profound changes in how people perceive themselves and the world at large, allowing them to recontextualize previous experiences and move forward from traumas that were holding them back.
Although prior research has done little to explore how psychedelic use can affect day-to-day life, the recent study indicates that psilocybin use may encourage full-time workers to prioritize their work-life balance and refrain from putting any extra effort into their work. Rather than going over and above by either taking on extra work, being proactive in meetings or spending as much time at the office, individuals are prioritizing their mental health, relationships, and personal well-being.
While this shift is undoubtedly beneficial for typically stressed and overworked employees, it is sending waves of panic through board rooms and the C-suite.
As companies such as Compass Pathways PLC (NASDAQ: CMPS) conduct further studies on these psychedelic substances, much more is likely to come to light regarding the beneficial effects that can arise when people use controlled doses of hallucinogens.
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
In the U.S., the medical authority determines the “standard of care” for conventional, allopathic medicine.
The Standard of Care is a degree of care a doctor is expected to exercise. Standard of Care is based on many things: practice guidelines, the medical literature, hospital policies and procedures, state and federal regulations, and other sources.
A 2005 article in the Journal of the American Academy of Psychiatry and the Law states that, “The precise definition of the standard of care varies from one state to another… Practice guidelines evolve and change, driven by new developments in clinical practice and science… After 5.8 years, half of the practice guidelines are outdated.”
In reality, standards do not exist. Opinions are what matters, especially in a world where patients can get a second or third or fourth medical opinion for each diagnosis. Opinions are like noses, everyone has one.
However, in the Covidian Age, all previous opinions on national healthcare guidance are being replaced by one opinion from a global perspective; the World Health Organization. As we go into the Fall “flu season,” all opinions promote the “updated” COVID vaccines, such as this: “FDA signs off on updated Covid-19 vaccines that target circulating variants.” However, opinions are always in flux.
However, the science has a different opinion. Contrary to media reports, the 2nd generation monovalent mRNA booster shots do not target the current dominant variants. Furthermore, they come without safety testing.
According to Johns Hopkins report, because all viruses mutate, “none of the variants circulating right now are exact matches to the vaccine.“
Using the words “updated COVID vaccine” rather than “COVID booster” also emphasizes that recipients of the minimally-tested new shots aren’t just boosting existing immunity from the same previous shots, but rather a completely new immune response—from a completely new medical product—to the newly-circulating variants.
Is this Standard of Care or an ongoing experiment?
mRNA Damage Reports
Meanwhile, fallout from the experimental mRNA mass vaccine campaign is showing up as collateral damage in studies hidden from view.
In September 2023, the headline read: ‘Researchers are alarmed to find DNA contamination in the Pfizer vaccine.” Phillip Buckhaults, a PhD in cancer genomic research, testified in a South Carolina Senate hearing that vaccinated people need to be tested to see if any of the foreign DNA has integrated into the genome of their stem cells, which s easily detectable because the foreign DNA has a unique signature. One senator responded:
We are not going to have any authority over the FDA to force Pfizer to do something. I mean, that’s a federal issue. – Senator Richard Cash, South Carolina
According to a March 2021 British Medical Journal study, some batches of mRNA vaccine were shown to have substantially lower mRNA integrity, with some saying these vaccines have been associated with greater adverse events.
With no real Standard of Care in allopathic medicine, it is little wonder that everyone has a different opinion and that vaccine failures persist. This is the reason why a universal flu vaccine never caught on and there has never been an attempt to create a vaccine for the common cold.
Under the Germ Theory, viruses mutate. Conventional medicine says there are more than 200 viruses thought to cause symptoms of the common cold. Thus, the flu vaccine has had a dismal track record year after year because science is always trying to catch up to the new variant. The truth is that vaccines induce variants to become “breakthrough infections.” That is the reason vaccinated people can still get the disease for which they are vaccinated.
New research suggests that “imperfect” or “leaky” vaccines – ones that don’t make their hosts totally immune to disease and incapable of spreading it to others – might have a surprising downside.
A December 2001 study in the Journal Nature upgrades “leaky” vaccines to “breakthrough infections.”
Not widely publicized, the COVID-SARS2 vaccines can increase your risk of “breakthrough infections,” while continuing to test positive for COVID and variants.methodshop from Pixabay” width=”300″ height=”200″>
Interestingly, the evidence showed that these breakthrough infections with the B.1.1.7 variant occurred slightly more often in people after the first vaccine dose compared to unvaccinated people.
They identified nearly 250 instances [out of 800 tests] in which an individual became infected with SARS-CoV-2 after receiving their first vaccine dose, meaning that they were only partially protected. Almost 150 got infected sometime after receiving the second dose.
Fall Forward
This Fall, health authorities warn that the highly mutated BA.2.86 variant may be more capable than its predecessors to cause infection in people who have been vaccinated for COVID.
Robin Higgins from Pixabay” width=”266″ height=”177″>
So, before allowing officials to determine your choice for you, do your own research and take your time to consider your options, including the wait-and-see approach. What is behind the needle? What do the studies report? Are there any studies to report?
When it comes to all vaccines, there is no liability for damages resulting from vaccine makers or doctors, no informed consent to patients, little to no data on vaccine trials, no insurance coverage for experimental procedures, and no Standard of Care.
The experiment is not over. Therefore, reflect before you inject.
Disclaimer: The information in this article is not intended as medical advice. Readers assume sole responsibility for choosing for themselves and their children disease prevention options that are compatible with their convictions.
Lexaria’s patented DehydraTECH(TM)-processed CBD has shown its ability to lower blood pressure in patients over multiple weeks
This technology has also shown positive impacts in obese diabetic-conditioned animals from its DIAB-A22-1 pre-clinical study
The NIC-H22-1 human nicotine study also demonstrated a statistically significant difference to achieve maximum blood saturation
These results have demonstrated DehydraTECH’s potential while propping it to take advantage of vastly untapped markets with potential for growth in the coming years
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is steadily advancing its patented DehydraTECH(TM) technology for its growing range of applications, which include oral nicotine, hypertension, antivirals, human hormone therapy, diabetes and more. The progress achieved thus far has been the product of years of clinical and pre-clinical research, all of which reflect management’s confidence in the company’s direction and technology.
As of the three months ended May 31, 2023, the company had increased its research and development (“R&D”) expenses by 118% year-over-year, primarily focused on the execution of hypertension, oral nicotine, and diabetes studies (https://cnw.fm/WUofP). This devotion of a significant proportion of its resources reflects the company’s intent to establish areas of investigation for commercial pursuits while bringing it closer to tapping into vastly untapped markets with the potential for growth in the coming years.
The investments have paid off, with Lexaria having come a step closer to submitting its Investigational New Drug (“IND”) application for its planned U.S. Phase 1b Hypertension Clinical Trial with the U.S. Food and Drug Administration (“FDA”) (https://cnw.fm/O4cn5). So far, previous clinical trials have shown DehydraTECH-processed CBD’s ability to lower blood pressure in patients over multiple weeks, a tremendous achievement for the company and for its technology.
“That we were able to lower blood pressure in our patient population over multiple weeks using DehydraTECH-CBD is an exceptional discovery, given that previous studies by others using other oral CBD formulations have failed to evidence this sustained benefit,” noted Chris Bunka, Lexaria’s CEO (https://cnw.fm/T5Hj3).
This success has been replicated in other studies, most notably diabetes. In Lexaria’s pre-clinical diabetes study, DIAB-A22-1, conducted in obese diabetic-conditioned animals, DehydraTECH-CBD yielded successful results showing positive impacts on blood glucose levels, overall body weight, locomotor activity, in addition to triglyceride and blood urea nitrogen levels. With the American Diabetes Association (“ADA”) estimating the number of Americans with diabetes at 37.3 million as of 2019, there is a dire need for viable treatment options, and Lexaria is looking to address that (https://cnw.fm/YwMuD).
Lexaria’s DehydraTECH has also proven its superiority and advantage over traditional oral delivery methods in the nicotine replacement market. Its NIC-H22-1 human nicotine study demonstrated a statistically significant difference between the time taken to achieve maximum blood saturation levels (“Tmax”) for DehydraTECH-nicotine at 2.3 and 3.1 minutes faster than alternatives currently in the market. In addition, DehydraTECH-nicotine represented a 15% and 20% faster response to achieve maximum blood saturation, a feat that few other players in the market have achieved.
“Within just five short years of R&D and product development, Lexaria has been able to develop an oral nicotine product that meets or exceeds the performance of the world’s leading existing brands,” noted Mr. Bunka.
“This is a remarkable achievement that speaks to the capabilities of the DehydraTECH technology and also to the Lexaria R&D team, working ardently with scarce resources relative to global multi-billion-dollar behemoths,” he added (https://cnw.fm/Mthe9).
Even with its achievements so far, Lexaria remains committed to pushing the envelope regarding the research and development of its DehydraTECH technology. So far, it has demonstrated its incredible potential across various areas of application as well as its viability in the market. The consistent push for further development reflects Lexaria’s understanding of its mission and commitment to creating shareholder value.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
Launched in 2020, CertiCraft is a seed-to-sale solution for licensed cannabis producers who want to streamline operations and save hours on monthly reporting.
Founded by a team of long-time cannabis lovers that brings a blend of experience and expertise, CertiCraft’s CEO, Sami Majadla, says what sets the company apart is its simplicity.
“Our in-house talent has allowed us to create the simplest compliance solution that saves Canadian growers & processors as much time and headache as possible,” says Majadla.
The company began as an idea in 2018, taking several years to build out into the founders’ vision of creating a reliable solution for compliance with a simple, functional interface, explains Majalda.
“Neither of those things existed when we started our business, and to date, CertiCraft is the only solution that checks off those two boxes,” he adds. “Our journey began with a mission to help craft cannabis producers transition into and thrive within the regulated market, which is still our north star today.”
The company currently provides services for several licensed producers, including micro cultivators and larger producers. The team brings years of experience in design, regulatory compliance, and software development, coupled with policy advocacy work, such as working with the BC LDB to drop the requirement for recall insurance and, of course, a love of cannabis.
“On the surface level, our in-house talent has allowed us to create the simplest compliance solution that saves Canadian growers & processors as much time and headache as possible,” continues Majalda. “However, it goes deeper than that with CertiCraft. We are at the forefront of policy advocacy work and have been fighting for our clients for years. Our team’s work has directly led to significant changes for our industry, and we support our clients in manners that you rarely see from a software company.”
“We are also the only service that allows our customers to generate all the paperwork they need to complete a Health Canada or CRA audit or inspection in just one minute; plus, we have exceptional customer support where our customers get what they need within a business day.”
Majalda says the amount of paperwork required for license holders in the cannabis space can be overwhelming. And while the company has built solutions for their clients to navigate this sea of paperwork, he says they would prefer to see some of these requirements lowered for producers.
“CertiCraft stays ahead by maintaining open channels with regulators and swiftly implementing updates to our platform when there are changes. Additionally, our significant policy advocacy work also allows us to proactively change cannabis policies in ways that hugely help the industry.”
Despite challenging regulations and a highly competitive market, CertiCraft still focuses on its roots in the cannabis culture.
“Above all else, we love the people working in the craft cannabis space. Many of our team members have rich histories in the world of cannabis, and we care deeply about seeing everybody who has transitioned into the legal market succeed in a market where the odds are stacked against them. We regularly get feedback from our customers telling us how much of a difference we make for them, and the heartwarming messages that we receive keep us going.
“We expect that within 2-3 years, we’ll arrive at a market that is no longer over-taxed and where there are reliable distribution channels for small-scale producers. We expect this will lead to a second wave of operators transitioning from traditional/legacy markets into regulated ones.”
Edmonton — Shares of Aurora Cannabis Inc. were down more than 10 per cent after the cannabis company announced plans to raise $33.8 million in a share offering.
The company says Canaccord Genuity has agreed to buy, on a bought deal basis, 46,250,000 shares of the company at a price of 73 cents per share.
It has also granted Canaccord Genuity an over-allotment option for up to an additional 6,937,500 shares on the same terms. If the over-allotment option is exercised in full, the offering will total $38.8 million.
Aurora says it plans to use the money raised to repay the remainder of its outstanding convertible senior notes at or prior to maturity.
Advertisement
The company says the remainder, if any, will be used for strategic purposes, including potential acquisitions.
Aurora’s stock price was down 13 per cent at 79 cents per share in early trading on the Toronto Stock Exchange.
Here you can find a selection of cannabis scientific studies published in the latest month. Each article is correlated with a short abstract describing the purpose of the study and the main research findings.A great cannabis culture comes from great and peer reviewed sources! For this reason we believe in the importance of consulting reliable sources. Whether you are interested in a particular article don’t hesitate to read the full piece for more information.
Cannabis and Health ⎯ Best new findings
Cannabis Use: A Marker of Clinical Severity in Inflammatory Bowel Disease?
This research was conducted utilizing a propensity score – matching methodology in order to identify the risk associated with the cannabis consumption and the emergency department visits, hospitalization, opioid use and corticosteroid use in patients with inflammatory bowel disease (IBD). The study found that there wasn’t an increasing risk of mortality of or surgery, nevertheless it is supposed that cannabis use could potentially be an indicator of the disease severity. More studies and different methods should be applied in order to fully reveal a correlation between IBD severity and cannabis use.
Effects of Smoking Marijuana on the Respiratory System: A Systematic Review
This systematic review presents the issues of cannabis use linked with respiratory health. Cannabis smoking negatively impacts lung function and leads to various respiratory problems including pneumonia, emphysema, asthma and chronic obstructive pulmonary disease. The prolonged consumption of cannabis through combustion/inhalation increases the risks of respiratory function impairment. The correlation between cannabis use and lung cancer is weak and more extensive research should be done to clarify all the possible risks. From this research review it is clear that the recreational consumption of cannabis should be discouraged, mainly among young adults.
Δ9-Tetrahydrocannabinol Effects on Respiration and Heart Rate Across Route of Administration in Female and Male Mice
The characterization of the impact of sex and administration route of tetrahydrocannabinol (THC)-induced changes in cardiopulmonary phenotypes in mice. The heart rate and respiration were monitored in the same mice group experimenting the administrations of THC through aerosol, oral gavage, intraperitoneal and subcutaneous injection. From this study results that all the different administration routes altered the respiratory volume and the heart rate , with effects linked to the amount of THC administered. Interestingly the effects of aerosolized THC were short lived but the first to onset, together with the intraperitoneal THC administration. An important trend was that while THC decreased respiration and heart rate, female mice given oral gavage THC showed increased heart rate. This kind of study is important to establish the differences in timeline and cardiopulmonary response to THC following the most common preclinical routes of administration.
Identification and Quantification of the Main Psychoactive Ingredients of Cannabis in Urine Using Excitation–Emission Matrix Fluorescence Coupled with Parallel Factor Analysis
This study reports the use of excitation-emission matrix (EEM) fluorescence spectroscopy coupled with parallel factor (PARAFAC) analysis to identify and quantify cannabinoids in urine samples. The analyzed cannabinoids included cannabidiol (CBD), cannabinol (CBN), tetrahydrocannabinol (THC) and tetrahydrocanabinolic acid (THC-COOH). The reported method is solventless, reliable, fast and it is capable of performing an accurate analysis of cannabis abusers.
Recent advances in illicit drug detection sensor technology in water
This research investigates new methods to successfully detect illicit drugs such as opioids, amphetamines, cannabis and cocaine in wastewater. Using electrochemical and optical sensors it is possible to detect these substances, cutting the costs and the time of traditional analytical methods such as liquid chromatography coupled with mass spectrometry (LC-MS), or gas chromatography coupled with mass spectrometry (GC-MS) or high-performance liquid chromatography (HPLC). Despite the high sensitivity and precision of these methods these machineries require skilled technicians, are quite expensive and not portable. Monitoring wastewater on site with alternative analytical methods could help evaluating the environmental impact of these substances, but could be also useful to track illegal drug use.
Solvent extraction of Cannabis sativa under cryogenic conditions
This study focuses on the cryogenic extraction of cannabis inflorescences using ethanol as solvent. At room temperature ethanol extracts chlorophyll together with cannabinoids, while at low temperatures this solvent can be more selective for cannabinoids and other cannabis constituents such as terpenes and flavonoids. In this research various extraction temperature have been tested going from −80 °C to 20 °C. All the data regarding cannabinoid and terpene quantification are reported for each different operating temperature. The best conditions were found at -20 °C and a solvent/solid ratio of 16:1 mL/g.
Hemp seed (Cannabis sativa L.) cake as sustainable dietary additive in slow-growing broilers: effects on performance, meat quality, oxidative stability and gut health
The aim of this study was to evaluate the effects of dietary inclusion of hemp seed cake on slow-growing broilers. The quality of the meat wasn’t affected by this change in the diet of broilers. Hemp seed cake influenced positively the lipid profile of the meat and improved the oxidative status and gut health, representing an interesting and valuable alternative ingredient in slow-growing broilers.
Endocannabinoid System Receptors at the Hip and Stifle Joints of Middle-Aged Dogs: A Novel Target for the Therapeutic Use of Cannabis sativa Extract in Canine Arthropathies
This research investigates the presence of specific endocannabinoid system receptors in the joints of middle-aged dogs. These receptors, including CB1R, CB2R, and GPR55, appear to be promising targets for therapeutic interventions using cannabis derived extracts against arthropathies in dogs. This study confirms the important role of the endocannabinoid system as therapeutic target of veterinary medicine for a wide variety of physiological issues including pain, inflammation, neurological functions and immune functions.
Pharmacokinetic modeling of orally administered cannabidiol and implications for medication control in horses
The goal of this research study was to evaluate the pharmacokinetic properties of cannabidiol (CBD) following oral administration in horses, in order to produce data to help anti-doping control laboratories to interpret analysis results. The need for this kind of research is because cannabinoids are banned in equine sports and limited info is available regarding the CBD detection time in urine and blood samples. The mixed approach used for population pharmacokinetic analysis exploited a non-linear mixed-effects model and non-compartmental analysis. The concentrations of CBD and its metabolites were evaluated using gas-chromatography coupled with mass spectrometry.
Two Republican lawmakers have filed a measure that would force federal agencies to receive Congressional approval before they can reschedule cannabis. The Deferring Executive Authority (DEA) Act is sponsored by Senators Steve Daines and Cynthia Lummis, who provided brief previews of the measure during statements regarding the Secure and Fair Enforcement Regulation (SAFER) Banking Act.
The recently introduced measure would require any federal agency interested in rescheduling cannabis to first submit to Congress its proposal for transferring the Schedule I drug from one classification to another. Congressional lawmakers would have the chance to review the proposal and would be granted 60 session days to block the measure’s enactment via a joint resolution if they opposed it.
The two lawmakers introduced the measure weeks after the U.S. Department of Health & Human Services (HHS) recommended that the DEA reclassify marijuana to a lower schedule due to its proven medical applications and lower abuse potential. Lummis said in a press statement that Congress is in charge of crafting laws for the nation, “not DC bureaucrats.”
The DEA Act would allow Americans to “have the final say” on something as significant as cannabis legalization through their elected leaders.
Cannabis has been a controversial topic since states began legalizing the plant more than 20 years ago. While the cannabis movement enjoyed strong support from the reform movement and younger generations, many conservatives and even Democrats weren’t comfortable with the idea of legalizing a drug they considered dangerous and a gateway to criminal activity.
However, surveys now show that a majority of Americans support at least decriminalizing the plant, something that has become clearer as voters in state after state choose to legalize cannabis for either medical or recreational uses. In addition, President Biden based part of his campaign platform on decriminalizing cannabis and putting a final end to the era of cannabis prohibition. However, the administration has been accused of dragging its feet when it comes to cannabis.
The HHS’s recent recommendation to ease federal marijuana restrictions was part of a 2022 request by the Biden administration to review the nation’s federal marijuana classification. Although cannabis is now legal in dozens of states, federal law still considers it a Schedule I drug with no medical application.
Several lawmakers including Senate Majority Leader Chuck Schumer have pledged to introduce legislation to legalize cannabis at the federal level. However, Lummis said that the Biden administration’s race to reschedule the controversial plant seems to be steeped in political rather than scientific reasons.
Lummis was part of a group of GOP Senate and House lawmakers who sent the DEA a letter asking the administrator to reject the Department of Health and Human Services’ request to reschedule cannabis.
Marijuana companies such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) are probably waiting to see the final position that the DEA communicates regarding the cannabis scheduling review process since that change could have major implications on how they conduct their operations.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 844-397-5787 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
Tumisu from 
methodshop from 
Robin Higgins from 
Recent Comments